Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

2.

A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C.

Koh C, Dubey P, Han MAT, Walter PJ, Garraffo HM, Surana P, Southall NT, Borochov N, Uprichard SL, Cotler SJ, Etzion O, Heller T, Dahari H, Liang TJ.

Antiviral Res. 2019 Mar;163:149-155. doi: 10.1016/j.antiviral.2019.01.017. Epub 2019 Jan 31.

PMID:
30711416
3.

Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis.

Gambato M, Canini L, Lens S, Graw F, Perpiñan E, Londoño MC, Uprichard SL, Mariño Z, Reverter E, Bartres C, González P, Pla A, Costa J, Burra P, Cotler SJ, Forns X, Dahari H.

Liver Int. 2018 Nov 30. doi: 10.1111/liv.14014. [Epub ahead of print]

PMID:
30499631
4.

Accounting for Space—Quantification of Cell-To-Cell Transmission Kinetics Using Virus Dynamics Models.

Kumberger P, Durso-Cain K, Uprichard SL, Dahari H, Graw F.

Viruses. 2018 Apr 17;10(4). pii: E200. doi: 10.3390/v10040200.

5.

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K.

Hepatology. 2018 Aug;68(2):473-484. doi: 10.1002/hep.29891. Epub 2018 Jun 6.

PMID:
29572897
6.

Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms.

Aunins TR, Marsh KA, Subramanya G, Uprichard SL, Perelson AS, Chatterjee A.

J Virol. 2018 May 14;92(11). pii: e02098-17. doi: 10.1128/JVI.02098-17. Print 2018 Jun 1.

7.

Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.

Canini L, Koh C, Cotler SJ, Uprichard SL, Winters MA, Han MAT, Kleiner DE, Idilman R, Yurdaydin C, Glenn JS, Heller T, Dahari H.

Hepatol Commun. 2017 May 19;1(4):288-292. doi: 10.1002/hep4.1043. eCollection 2017 Jun.

8.

HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.

Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K.

PLoS One. 2017 Dec 7;12(12):e0187409. doi: 10.1371/journal.pone.0187409. eCollection 2017.

9.

The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?

Nguyen THT, Guedj J, Uprichard SL, Kohli A, Kottilil S, Perelson AS.

Sci Rep. 2017 Aug 31;7(1):10233. doi: 10.1038/s41598-017-09776-z.

10.

Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Goyal A, Lurie Y, Meissner EG, Major M, Sansone N, Uprichard SL, Cotler SJ, Dahari H.

Antiviral Res. 2017 Aug;144:281-285. doi: 10.1016/j.antiviral.2017.06.019. Epub 2017 Jun 30.

11.

Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies.

Malespin M, Benyashvili T, Uprichard SL, Perelson AS, Dahari H, Cotler SJ.

Therap Adv Gastroenterol. 2017 Jan;10(1):68-73. doi: 10.1177/1756283X16672392. Epub 2016 Oct 17.

12.

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report.

Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y.

World J Hepatol. 2016 Jul 18;8(20):858-62. doi: 10.4254/wjh.v8.i20.858.

13.

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

DebRoy S, Hiraga N, Imamura M, Hayes CN, Akamatsu S, Canini L, Perelson AS, Pohl RT, Persiani S, Uprichard SL, Tateno C, Dahari H, Chayama K.

J Viral Hepat. 2016 Sep;23(9):708-17. doi: 10.1111/jvh.12551. Epub 2016 Jun 8.

14.

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.

Dahari H, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P.

J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.

15.

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T.

Lancet Infect Dis. 2015 Oct;15(10):1167-1174. doi: 10.1016/S1473-3099(15)00074-2. Epub 2015 Jul 16.

16.

Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach.

Graw F, Martin DN, Perelson AS, Uprichard SL, Dahari H.

J Virol. 2015 Jul;89(13):6551-61. doi: 10.1128/JVI.00016-15. Epub 2015 Apr 1.

17.

Hepatitis C virus Cell-to-cell Spread Assay.

Barretto N, Uprichard SL.

Bio Protoc. 2014 Dec 20;4(24). pii: e1365. doi: 10.21769/BioProtoc.1365.

18.

Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment.

Uprichard SL, Sainz B Jr.

Gut. 2015 Apr;64(4):690-1. doi: 10.1136/gutjnl-2014-308396. Epub 2014 Oct 6. No abstract available.

PMID:
25287483
19.

Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Sabahi A, Uprichard SL, Wimley WC, Dash S, Garry RF.

J Virol. 2014 Sep;88(18):10280-8. doi: 10.1128/JVI.00874-14. Epub 2014 Jul 2. Review.

20.

Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.

Barretto N, Sainz B Jr, Hussain S, Uprichard SL.

J Virol. 2014 May;88(9):5050-61. doi: 10.1128/JVI.03241-13. Epub 2014 Feb 19.

21.

Establishment of mice with inheritable susceptibility to productive hepatitis C virus infection.

Uprichard SL.

Hepatology. 2014 May;59(5):2043-6. doi: 10.1002/hep.26949. Epub 2014 Mar 27. No abstract available.

PMID:
24277664
22.

High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.

Lee H, Zhu T, Patel K, Zhang YY, Truong L, Hevener KE, Gatuz JL, Subramanya G, Jeong HY, Uprichard SL, Johnson ME.

PLoS One. 2013 Oct 9;8(10):e75144. doi: 10.1371/journal.pone.0075144. eCollection 2013.

23.

The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate.

Guedj J, Dahari H, Uprichard SL, Perelson AS.

Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):397-9. doi: 10.1586/17474124.2013.811050. No abstract available.

24.

Identification of transferrin receptor 1 as a hepatitis C virus entry factor.

Martin DN, Uprichard SL.

Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10777-82. doi: 10.1073/pnas.1301764110. Epub 2013 Jun 10.

25.

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.

26.

Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay.

Yu X, Sainz B Jr, Petukhov PA, Uprichard SL.

Antimicrob Agents Chemother. 2012 Dec;56(12):6109-20. doi: 10.1128/AAC.01413-12. Epub 2012 Sep 4.

27.

New hepatitis C virus drug discovery strategies and model systems.

Hussain S, Barretto N, Uprichard SL.

Expert Opin Drug Discov. 2012 Sep;7(9):849-59. doi: 10.1517/17460441.2012.711312. Epub 2012 Aug 4. Review.

28.

Permissiveness of human hepatoma cell lines for HCV infection.

Sainz B Jr, Barretto N, Yu X, Corcoran P, Uprichard SL.

Virol J. 2012 Jan 24;9:30. doi: 10.1186/1743-422X-9-30.

29.

Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.

Nat Med. 2012 Jan 8;18(2):281-5. doi: 10.1038/nm.2581.

30.

Potential treatment options and future research to increase hepatitis C virus treatment response rate.

Tencate V, Sainz B Jr, Cotler SJ, Uprichard SL.

Hepat Med. 2010 Oct;2010(2):125-145.

31.

Hepatitis C virus experimental model systems and antiviral drug research.

Uprichard SL.

Virol Sin. 2010 Aug;25(4):227-45. doi: 10.1007/s12250-010-3134-0. Epub 2010 Jul 28. Review.

32.

Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.

Yu X, Uprichard SL.

Curr Protoc Microbiol. 2010 Aug;Chapter 17:Unit 17.5.. doi: 10.1002/9780471729259.mc1705s18.

33.

The rate of hepatitis C virus infection initiation in vitro is directly related to particle density.

Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, Yu X, Garry RF, Uprichard SL.

Virology. 2010 Nov 10;407(1):110-9. doi: 10.1016/j.virol.2010.07.026. Epub 2010 Aug 25.

34.

A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD.

J Virol. 2010 Aug;84(15):7513-22. doi: 10.1128/JVI.00200-10. Epub 2010 May 26.

35.

Hepatitis C virus infection in phenotypically distinct Huh7 cell lines.

Sainz B Jr, Barretto N, Uprichard SL.

PLoS One. 2009 Aug 10;4(8):e6561. doi: 10.1371/journal.pone.0006561.

36.

Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening.

Yu X, Sainz B Jr, Uprichard SL.

Antimicrob Agents Chemother. 2009 Oct;53(10):4311-9. doi: 10.1128/AAC.00495-09. Epub 2009 Jul 20.

37.

Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection.

Sainz B Jr, TenCate V, Uprichard SL.

Virol J. 2009 Jul 15;6:103. doi: 10.1186/1743-422X-6-103.

38.

Developmental regulation of hepatitis B virus biosynthesis by hepatocyte nuclear factor 4alpha.

Li L, Oropeza CE, Sainz B Jr, Uprichard SL, Gonzalez FJ, McLachlan A.

PLoS One. 2009;4(5):e5489. doi: 10.1371/journal.pone.0005489. Epub 2009 May 8.

39.

Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon.

Dahari H, Sainz B Jr, Perelson AS, Uprichard SL.

J Virol. 2009 Jul;83(13):6383-90. doi: 10.1128/JVI.02612-08. Epub 2009 Apr 15.

40.

Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Rothwangl KB, Manicassamy B, Uprichard SL, Rong L.

Virol J. 2008 Mar 20;5:46. doi: 10.1186/1743-422X-5-46.

41.

Replication of a hepatitis C virus replicon clone in mouse cells.

Uprichard SL, Chung J, Chisari FV, Wakita T.

Virol J. 2006 Oct 28;3:89.

42.

The therapeutic potential of RNA interference.

Uprichard SL.

FEBS Lett. 2005 Oct 31;579(26):5996-6007. Epub 2005 Aug 15. Review.

43.

Robust hepatitis C virus infection in vitro.

Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9. Epub 2005 Jun 6.

44.

Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.

Uprichard SL, Boyd B, Althage A, Chisari FV.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):773-8. Epub 2005 Jan 7.

46.

Transcriptional and posttranscriptional control of hepatitis B virus gene expression.

Uprichard SL, Wieland SF, Althage A, Chisari FV.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1310-5. Epub 2003 Jan 27.

47.

Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures.

Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV.

J Virol. 2002 Jun;76(11):5646-53.

48.

Comparison of the intranuclear distributions of herpes simplex virus proteins involved in various viral functions.

de Bruyn Kops A, Uprichard SL, Chen M, Knipe DM.

Virology. 1998 Dec 5;252(1):162-78.

49.

The role of herpes simplex virus ICP27 in the regulation of UL24 gene expression by differential polyadenylation.

Hann LE, Cook WJ, Uprichard SL, Knipe DM, Coen DM.

J Virol. 1998 Oct;72(10):7709-14.

50.

Supplemental Content

Loading ...
Support Center